Although several studies have shown that CYP2C19*2 and CYP2C19*3 polymorphisms influence the platelet response to clopidogrel [23]–[28], clinical data concerning the relevance of CYP2C19*2 and CYP2C19*3 carrier status in patients with CAD after PCI are limited, especially in China. Here, CYP2C19 is linked to coronary artery disorder.